EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution

Arianna Rodríguez-Coello iD, Michelle Outeda-García iD, Andrea García-Pose iD, Lucía Gonzalez-Pinto iD, Gabriela Alejandra Báez-Barroso iD, Paula Guijarro-Sánchez iD, Andrea Muras iD, Biel Taltavull, Pablo Fraile-Ribot iD, Isaac Alonso-Garcia iD, Antonio Oliver iD, Juan Carlos Vázquez-Ucha iD und 3 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00724-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Arianna Rodríguez-Coello und 14 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain. Hauptthemen laut MEDLINE: Cephalosporins, Ceftazidime, Pseudomonas aeruginosa, Azabicyclo Compounds. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III, Axencia Galega de Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a murine bacteremia model. Cefiderocol achieved greater bacterial reductions in parental isolates than in E219K derivatives, despite susceptible MICs. Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo , supporting close monitoring of cefiderocol activity against isolates carrying this variant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsCeftazidimePseudomonas aeruginosaAzabicyclo CompoundsTazobactamAnti-Bacterial Agentsbeta-LactamasesBacterial ProteinsCefiderocolAnimalsMicrobial Sensitivity TestsDrug CombinationsPseudomonas InfectionsThird Generation CephalosporinsMiceDrug Resistance, Multiple, BacterialBacteremiaPenicillanic Acid

Stichwörter der Autor:innen

E219KPDCPseudomonas aeruginosacefiderocolceftazidime/avibactamceftolozane/tazobactammurine infection

Substanzen

CephalosporinsCefiderocolCeftazidimeAzabicyclo CompoundsTazobactamAnti-Bacterial Agentsbeta-LactamasesDrug Combinationsavibactam, ceftazidime drug combinationThird Generation Cephalosporins

Autor:innen und Institutionen

  • Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Microbiología Hospital Universitario Son Espases Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidad de A Coruña, A Coruña, Spain.

ORCID-Profile: Arianna Rodríguez-Coello, Michelle Outeda-García, Andrea García-Pose, Lucía Gonzalez-Pinto, Gabriela Alejandra Báez-Barroso, Paula Guijarro-Sánchez, Andrea Muras, Pablo Fraile-Ribot, Isaac Alonso-Garcia, Antonio Oliver, Juan Carlos Vázquez-Ucha, Jorge Arca-Suárez, Germán Bou, Alejandro Beceiro

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de Salud Carlos III
  • Axencia Galega de Innovación
  • Xunta de Galicia

Zitieren

APA

Rodríguez-Coello, A., Outeda-García, M., García-Pose, A., Gonzalez-Pinto, L., Báez-Barroso, G. A., Guijarro-Sánchez, P., Muras, A., Taltavull, B., Fraile-Ribot, P., Alonso-Garcia, I., Oliver, A., Vázquez-Ucha, J. C., Arca-Suárez, J., Bou, G., & Beceiro, A. (2026). In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00724-26

Vancouver

Rodríguez-Coello A, Outeda-García M, García-Pose A, Gonzalez-Pinto L, Báez-Barroso GA, Guijarro-Sánchez P, et al. In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00724-26

BibTeX
@article{RodrguezCoello2026,
  author = {Rodríguez-Coello, Arianna and Outeda-García, Michelle and García-Pose, Andrea and Gonzalez-Pinto, Lucía and Báez-Barroso, Gabriela Alejandra and Guijarro-Sánchez, Paula and Muras, Andrea and Taltavull, Biel and Fraile-Ribot, Pablo and Alonso-Garcia, Isaac and Oliver, Antonio and Vázquez-Ucha, Juan Carlos and Arca-Suárez, Jorge and Bou, Germán and Beceiro, Alejandro},
  title = {In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00724-26}
}
Kostenlos starten →